It is still too early to consider IGF-1 as the key factor; rather, literature is providing the clue suggesting that it is a good endeavour to pursue in order to achieve an appropriate pharmacological target that could aim at reversing MetS in parallel with diet and exercise before it onsets T2D. The gene discussed is IGF1; the disease is type 2 diabetes mellitus.